Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
The feasibility of magnetic resonance venography (MRV) for measuring change in thrombus volume with a novel anticoagulation regimen versus standard anticoagulation in patients with symptomatic deep vein thrombosis (DVT) has not been assessed. Our aim was to study the feasibility of MRV to measure change in thrombus volume in patients with acute symptomatic objectively confirmed proximal DVT in an open-label multicenter trial (edoxaban Thrombus Reduction Imaging Study, eTRIS). We randomized patients in a 2:1 allocation ratio to edoxaban 90 mg/day for 10 days followed by 60 mg/day versus parenteral anticoagulation bridging to warfarin for 3 months. The primary efficacy outcome was a surrogate end point of the relative change in MRV-quantified thrombus volume from baseline to Day 14–21. A total of 85 eligible patients from 26 study sites were randomized to edoxaban monotherapy ( n=56) versus parenteral anticoagulation as a ‘bridge’ to warfarin ( n=29). The mean relative change in MRV-quantified thrombus volume from baseline to Day 14–21 was similar in patients treated with edoxaban and parenteral anticoagulation as a ‘bridge’ to warfarin (−50.1% vs −58.9%; 95% confidence interval of treatment difference, −12.7%, 30.2%). However, thrombus extension was observed in eight patients in the edoxaban monotherapy group and in none in the warfarin group. Rates of recurrent venous thromboembolism (3.6% vs 3.6%, p=0.45) and clinically relevant non-major bleeding (5.4% vs 7.1%, p=0.34) were also similar. No major bleeds occurred in either on-treatment group during the study period. In conclusion, MRV can assess change in thrombus volume in patients with acute DVT randomized to two different anticoagulant regimens. ClinicalTrials.gov Identifier: NCT01662908 Investigational New Drug (IND) Application: Edoxaban IND # 63266
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [94]
The cited source says what the claim attributes to it.
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [94]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [94]
The cited source says what the claim attributes to it.
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Agnelli, G., Gallus, A., Goldhaber, S. Z., Haas, S., Huisman, M. V., Hull, R. D., Kakkar, A. K., Misselwitz, F., & Schellong, S. (2007) · Circulation · doi:10.1161/circulationaha.106.668020 · Cited by 337
Self-citationSampson, F. C., Goodacre, S. W., Thomas, S. M., & van Beek, E. J. R. (2007) · European Radiology · doi:10.1007/s00330-006-0178-5 · Cited by 172
Tan, M., Mol, G. C., van Rooden, C. J., Klok, F. A., Westerbeek, R. E., del Sol, A. I., van de Ree, M. A., Roos, A., & Huisman, M. V. (2014) · Blood · doi:10.1182/blood-2014-04-566380 · Cited by 103
Temme, S., Grapentin, C., Quast, C., Jacoby, C., Grandoch, M., Ding, Z., Owenier, C., Mayenfels, F., Fischer, J. W., Schubert, R., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.010962 · Cited by 95
Magnetic resonance direct thrombus imaging of the evolution of acute deep vein thrombosis of the leg
Westerbeek, R. E., van Rooden, C. J., Tan, M., van Gils, A. P. G., KOK, S., BATS, M. J. D., Roos, A., & Huisman, M. V. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02986.x · Cited by 83
Experience in 207 Combined MRI Examinations for Acute Pulmonary Embolism and Deep Vein Thrombosis
Kluge, A., Mueller, C., Strunk, J., Lange, U., & Bachmann, G. F. (2006) · American Journal of Roentgenology · doi:10.2214/ajr.05.0756 · Cited by 81 · cited 1×
“To determine locations and extent of thrombus, pre- and post-contrast 3D gradient echo sequences were acquired from: (1) the mid-calf to above the knee, (2) above the knee to the thigh and lower pelvis, and (3) thigh and lower pelvis to abdomen.”
MethodAbdalla, G. M., Matuk, R. F., Venugopal, V., Verde, F., Magnuson, T. H., Schweitzer, M., & Steele, K. E. (2015) · Clinical Radiology · doi:10.1016/j.crad.2015.04.007 · Cited by 42 · cited 1×
“To determine locations and extent of thrombus, pre- and post-contrast 3D gradient echo sequences were acquired from: (1) the mid-calf to above the knee, (2) above the knee to the thigh and lower pelvis, and (3) thigh and lower pelvis to abdomen.”
Method
Research works printed but not linked: 1
- Mani V, 2015, J Vis Exp, e52761
Cited by
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
ERS statement on chronic thromboembolic pulmonary hypertension
Delcroix, M., Torbicki, A., Gopalan, D., Sitbon, O., Klok, F. A., Lang, I., Jenkins, D., Kim, N. H., Humbert, M., Jais, X., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02828-2020 · Cited by 576
Can thrombus age guide thrombolytic therapy?
Czaplicki, C. D., Albadawi, H., Partovi, S., Gandhi, R. T., Quencer, K. B., Deipolyi, A. R., & Öklü, R. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.11.05 · Cited by 110
Gu, Z., Wei, A., Zhang, C., Wang, X., Zhang, L., Shen, L., Li, Z., Pan, M.-M., Liu, X.-Y., Pu, J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.056 · Cited by 111
Wang, X., Ma, Y., Xu, H., Li, M., Li, J., Tian, J., Wang, Q., Yan, P., Li, J., Xie, P., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010956.pub3 · Cited by 52
Metadata
- Authors
- Piazza, G., Mani, V., Goldhaber, S. Z., Grosso, M. A., Mercuri, M., Lanz, H. J., Schussler, S., Hsu, C., Chinigo, A., Ritchie, B., Nadar, V., Cannon, K., Pullman, J., Concha, M., Schul, M., Fayad, Z. A., & for the edoxaban Thrombus Reduction Imaging Study (eTRIS) Investigators
- Affiliations
- Brigham and Women's Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- Daiichi Sankyo Pharma Development, Edison, NJ, USA
- University of Alberta (CA)
- Lewin and Nadar Cardiology Associates, Camp Hill, PA, USA
- Wilmington Health, Wilmington, NC, USA
- St. James Healthcare (US)
- Intercoastal Medical Group, Sarasota, FL, USA
- Lafayette Regional Vein and Laser Center, Lafayette, IN, USA
- Corresponding author
- Piazza, Gregory
- ORCID
- Venue
- Vascular Medicine
- Publisher
- SAGE Publications
- Published
- 2016-07-07
- Volume
- 21
- Issue
- 4
- Pages
- 361-368
- ISSN
- 1358-863X (ISSN-L)
- 1477-0377
- PMC
- PMC4963800
- OpenAlex
- W2352106300
- Cited by
- 18
- References
- 15
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 6 · 2017: 2
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Vascular Medicine (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
- Keywords
- deep vein thrombosis, edoxaban, thrombus volume, magnetic resonance venography, thrombus resolution, parenteral anticoagulation, warfarin, thrombus extension, recurrent venous thromboembolism, bleeding risk
- MeSH terms
- Administration, Oral, Adult, Aged, Anticoagulants, Blood Coagulation, Drug Therapy, Combination, Feasibility Studies, Female, Heparin, Humans, Male, Middle Aged, Phlebography, Predictive Value of Tests, Pyridines, Thiazoles, Time Factors, United States, Warfarin, Treatment Outcome, Magnetic Resonance Angiography, International Normalized Ratio, Venous Thrombosis, Administration, Intravenous, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. https://app.cochat.ai/papers/10.1177/1358863x16645853
- The paper
- Piazza, G., Mani, V., Goldhaber, S. Z., Grosso, M. A., Mercuri, M., Lanz, H. J., Schussler, S., Hsu, C., Chinigo, A., Ritchie, B., Nadar, V., Cannon, K., Pullman, J., Concha, M., Schul, M., Fayad, Z. A., & for the edoxaban Thrombus Reduction Imaging Study (eTRIS) Investigators. (2016). Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study. Vascular Medicine. https://doi.org/10.1177/1358863x16645853
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.